A cancer research UK pharmacokinetic study of BPA-mannitol in patients with high grade glioma to optimise uptake parameters for clinical trials of BNCT

Autor: Garth Cruickshank, John C. Vickerman, Stuart Green, J. Doran, J. Hardie, C. Wojnecki, A. Chopra, M. Chester, Steven Ford, Allah Detta, Nicholas D. James, R. Braithwaite, G. Croswell, N. Graham, Nicholas P. Lockyer, Gavin Halbert, T. M. T. Sheehan, Desire Ngoga, R. Sugar, Alan V. Boddy, Heidi Steinfeldt, Mary Elliot, Z. Ghani
Přispěvatelé: Cruickshank, GS, Ngoga, D, Detta, A, Green, S, Boddy, A, 13th International Congress on Neutron Capture Therapy Florence, Italy 2-8 November 2008
Rok vydání: 2009
Předmět:
Zdroj: Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine. 67(7-8)
ISSN: 1872-9800
Popis: This paper describes results to-date from a human pharmacokinetic study which began recruitment in December 2007. Results are presented for a single patient recruited in December 2007. A second patient was recruited in July 2008 but detailed data are not available at the time of writing. The trial is an open-label, non-comparative, non-therapeutic study of BPA-mannitol in patients with high-grade glioma, who will be undergoing stereotactic brain biopsy as part of the diagnostic process before definitive treatment. The study investigates the route of infusion (intra-venous (IV) or intra-carotid artery) and in each case will assess the effect of administration of mannitol as a blood-brain barrier disrupter. All cohorts will receive a 2 h infusion of BPA-mannitol, and for some cohorts an additional mannitol bolus will be administered at the beginning of this infusion. Measurements are made by inductively coupled plasma mass spectrometry (ICP-MS) of10B concentration in samples of blood, urine, extra-cellular fluid in normal brain (via a dialysis probe), brain tissue around tumour and tumour tissue. Additional analysis of the tumour tissue is performed using secondary ion mass spectrometry (SIMS). The first patient was part of the cohort having intra-venous infusion without mannitol bolus. No serious clinical problems were experienced and the assay results can be compared with available patient data from other BNCT centres. In particular we note that the peak10B concentration in blood was 28.1 mg/ml for a total BPA administration of 350 mg/kg which is very consistent with the previous experience with BPA-fructose reported by the Helsinki group. Refereed/Peer-reviewed
Databáze: OpenAIRE
Externí odkaz: